{"id":"NCT00159822","sponsor":"Pfizer","briefTitle":"Voriconazole For Chronic Bronchopulmonary Aspergillosis","officialTitle":"Voriconazole For Primary Therapy Of Proven, Chronic Bronchopulmonary Aspergillosis, In Minimally Immunocompromised Or, Non-Immunocompromised Hosts","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2005-07","primaryCompletion":"2008-12","completion":"2008-12","firstPosted":"2005-09-12","resultsPosted":"2010-01-07","lastUpdate":"2010-01-20"},"enrollment":48,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Aspergillosis"],"interventions":[{"type":"DRUG","name":"Voriconazole","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"To evaluate the efficacy of voriconazole (VFend(R)) as first line treatment for proven chronic bronchopulmonary aspergillosis, in minimally immunocompromised or non-immunocompromised patients after 6 months of treatment i.e. chronic necrotizing pulmonary","primaryOutcome":{"measure":"Number of Subjects With Successful Global Outcome at 6 Months: Chronic Bronchopulmonary Aspergillosis","timeFrame":"at 6 months of treatment","effectByArm":[{"arm":"Voriconazole","deltaMin":13,"sd":null}],"pValues":[{"comp":"OG000","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":2},"locations":{"siteCount":18,"countries":["France"]},"refs":{"pmids":[],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1501061&StudyName=Voriconazole%20and%20Bronchopulmonary%20Aspergillosis%20"]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":48},"commonTop":["Visual impairment","Bronchitis","Haemoptysis","Vision blurred","Insomnia"]}}